Charles River Labs Intl diskutieren
Charles River Labs Intl
WKN: 939391 / Symbol: CRL / Name: Charles River Lb / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
166,10 €
-0,09 %
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $220.00 to $190.00. They now have a "buy" rating on the stock.
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $170.00 price target on the stock.
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) was upgraded by analysts at TD Cowen from a "hold" rating to a "buy" rating. They now have a $179.00 price target on the stock.
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) was upgraded by analysts at Cowen Inc from a "hold" rating to a "buy" rating.
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) was upgraded by analysts at Redburn Atlantic from a "neutral" rating to a "buy" rating. They now have a $182.00 price target on the stock, down previously from $188.00.
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $200.00 price target on the stock, up previously from $150.00.
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target raised by analysts at Evercore ISI from $170.00 to $180.00. They now have an "outperform" rating on the stock.
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target raised by analysts at Evercore ISI from $180.00 to $190.00. They now have an "outperform" rating on the stock.
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $195.00 price target on the stock, up previously from $142.00.
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating. They now have a $195.00 price target on the stock, up previously from $165.00.
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. They now have a $199.00 price target on the stock, up previously from $178.00.
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) had its price target raised by analysts at Barclays PLC from $195.00 to $210.00. They now have an "overweight" rating on the stock.
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) had its price target lowered by analysts at TD Cowen from $205.00 to $197.00. They now have a "buy" rating on the stock.
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) was upgraded by analysts at Argus from a "hold" rating to a "buy" rating.
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) was upgraded by analysts at Bank of America Corporation from a "neutral" rating to a "buy" rating. They now have a $225.00 price target on the stock.
Ratings data for CRL provided by MarketBeat
Neueste Beiträge
BTIG_Research in Workday, Inc. diskutieren